Background: Combined oral contraceptives (COCs) containing various progestogens
is much lower than the incidence of VTE during pregnancy and the postpartum period. 3, 4 The effect of COCs on the risk of thrombosis was traditionally thought to be solely related to the effects of estrogen on hemostatic factors. However, studies have indicated that the risk of VTE varies among women using COCs containing different progestogens. Given the popularity and widespread use of COCs, any increase in the relative risk of VTE for particular COC formulations could translate to an excess absolute risk of important magnitude.
The present review was conducted for a consultation held by the WHO to examine the venous and arterial risks of COCs, as part of the process of updating the WHO Medical Eligibility Criteria for Contraceptive
Use (WHO MEC) 5 ; the review and meta-analysis have been updated since the WHO consultation to include data published during the interim period. For women who wish to use COCs, the key clinical question is whether certain COC formulations might further increase the risk of VTE above that associated with other formulations. Although several other meta-analyses 6-9 on this question have been conducted, the present meta-analysis updates previous analyses and compares different formulations with a levonorgestrel user group rather than with a nonuser group. The objective of the present systematic review and meta-analysis was to estimate the risk for VTE among women using COCs containing different progestogens compared with COCs containing levonorgestrel.
| MATERIALS AND METHODS
In the present systematic review and meta-analysis, PubMed and the Cochrane Library databases were searched for all articles on the association between COC use and VTE in all languages published from database inception through September 15, 2016, using a combination of search terms for oral contraception and venous thrombosis (Table   S1 ). In addition, the reference lists from identified studies and key review articles were hand-searched for additional studies.
For the exposure, studies were included that reported results for users of COCs with low-dose ethinyl estradiol (dose <50 μg) coupled with one of the following progestogens: cyproterone acetate, desogestrel, dienogest, drospirenone, gestodene, norgestimate, or levonorgestrel. Studies were only included if the risk estimates were reported separately by COC formulation (including monophasic formulations that had the same dose of ethinyl estradiol in all active pills and multiphasic formulations that had varying doses of ethinyl estradiol throughout the cycle, provided they had the same progestogen). Studies were excluded if COCs containing 50 μg of ethinyl estradiol or more accounted for more than 10% of the total exposure. Also excluded were articles that only reported the risk of VTE among a mixed group of COC users with different progestogen-containing COCs (e.g., "third generation"), and articles where the reference group cited the use of COC with non-specified progestogens. [10] [11] [12] Five of the included studies did not clearly state the estrogen dose contained; one study 13, 14 case-control analyses for the same study population; in the present analysis, the risk estimates from the nested case-control studies were used because most of the cohort risk estimates were unadjusted.
The evidence was summarized and systematically reviewed using standardized abstraction forms. The studies were abstracted by two authors (MVD, NKT) and verified by another (KMC).
Potential sources of bias were assessed for individual studies and quality ratings (good, fair, or poor) were assigned using study-designspecific criteria developed by the United States Preventive Services Task Force. 37 When assessing selection bias in case-control studies, the potential for biased selection of cases and controls (for example, hospital controls vs community controls) and the response rate were considered. The assessment of selection bias in cohort studies involved consideration of whether the cohort represented the population it was taken from, whether the exposed and unexposed groups came from the same population, and whether the follow-up rate was adequate. for inclusion in the meta-analysis. When studies presented risk ratios for multiple COCs containing the same progestogen at a specific ethinyl estradiol dose, a combined risk ratio for that progestogen was calculated.
A random-effects model based on profile likelihoods was used to calculate pooled risk ratios. 38 The presence of statistical heterogeneity was assessed using the standard Cochran χ 2 test, and the magnitude of the heterogeneity was evaluated using the I 2 statistic. 39 The included studies reported different risk estimate measures (odds ratios, hazard ratios, relative risks, or rate ratios). Because VTE is very rare, all these measures provide similar estimates and were combined in a single meta-analysis.
The analyses were stratified by the specific progestogen formulations. For studies that reported multiple adjusted relative risk estimates, the maximally adjusted estimates were used in the primary analysis.
Sensitivity and subgroup analyses were conducted based on whether the study adjusted for body mass index, smoking, or duration of COC use (or assessed these variables as potential confounders and determined adjustment was not needed to test for small-study effects (a marker of potential publication bias).
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All analyses were performed using Stata/IC version 13.1 (StataCorp, College Station, TX, USA). P<0.05 was considered statistically significant.
| RESULTS
The search strategy identified 2447 unique citations (Fig. 1) . Following the evaluation of titles and abstracts and reference lists from key review articles, the full texts of 98 studies were reviewed. Twentytwo articles satisfied the review inclusion criteria: 17 case-control studies 13, 15, 16, 23, 29, 30, [32] [33] [34] [35] [36] [41] [42] [43] [44] [45] [46] (Table S2) , 10 of which were nested within a cohort study, and five cohort studies 3, 17, 24, 28, 31 (Table S3 ). Two cohort studies 3, 28 collected prospective population-based data with a specific study design; these studies were rated as being of "good" quality (Table S3 ). All case-control studies and one cohort study 31 offered evidence of "fair" quality, and the remaining two cohort studies were considered to be of "poor" quality (Tables S2 and S3 Full-text publications included in meta-analysis (n=22):
T A B L E 1 Summary of meta-analyses, sensitivity analyses, and subgroup analyses for the risk of venous thromboembolism among users of combined oral contraceptives by progestogen type compared with levonorgestrel. risk of VTE compared with the use of levonorgestrel-containing COCs ( Table 1 ). The use of dienogest was not significantly associated with an increased risk of VTE (Fig. S5) The findings were also generally consistent in other sensitivity and stratified analyses. The exclusion of poor-quality studies did not impact the pooled estimates of relative risks or reduce the heterogeneity (Table 1) . In stratified analyses, the pooled estimates of risk were generally lower in studies that adjusted for the body mass index, smoking, or the duration of use than in studies that did not adjust for these factors ( Table 1 ). The risk estimates were similar when studies were stratified according to the use of a case-control or cohort design; however, with the exception of deosgestrel and norgestimate, there were some differences in heterogeneity in analyses stratified by study design. Pooled estimates based on studies sponsored by the pharmaceutical industry typically indicated lower risks for VTE but more heterogeneity compared with studies not sponsored by the pharmaceutical industry. None of the differences in the stratified analyses were statistically significant ( 
| DISCUSSION
The present meta-analysis indicated that the use of low-dose (less ; therefore, it could be that some progestogens decrease the risk of VTE associated with ethinyl estradiol more than other progestogens do. Some studies have found progestogens to be associated with increases in the platelet count and platelet aggregation, whereas others have not. 48 Further research is needed to determine the hemostatic changes associated with different pill formulations, and to evaluate whether these changes translate into clinical differences in the risk of thrombosis.
T A B L E 2 Pooled estimates (95% confidence intervals) of unadjusted risk ratios for venous thromboembolism among users of combined oral contraceptives by progestogen type compared with levonorgestrel in published meta-analyses. Estimates are given as risk ratios.
The present meta-analysis used adjusted risk estimates to reduce potential confounding. Four other meta-analyses 6,7,9,49 have also estimated pooled relative risks for VTE associated with a specific COC formulation compared with a levonorgestrel-containing formulation, but have used unadjusted estimates ( Table 2) . Although each used different methods and varied in the individual studies included, the findings are generally similar. Two of the meta-analyses 7, 9 found no increase in the risk of VTE with norgestimate-containing COCs compared with levonorgestrel-containing pills, which is consistent with the present findings. Similarly, the present findings of slight increases in relative risk for desogestrel, drospirenone, and gestodene are consistent with results from the previous metaanalyses, 6,7,9,49 which found small but significantly increased (range 1.3-1.9) relative risks associated with these progestogens. The present estimate for cyproterone acetate was slightly higher (risk ratio 2.0), but generally consistent with the estimates from two other analyses (risk ratio 1.6-1.7). 7, 9 The present analysis had limitations. There are no data from randomized controlled trials; thus, the analysis was limited to comparative observational trials of overall fair quality, which could have resulted in biased results. However, given that VTE is very rare among women of reproductive age, no randomized controlled trials have previously been conducted to investigate this association, and appropriately powered trials would likely be extremely resource-intensive, limiting their feasibility. It was attempted to reduce bias by including only studies that accounted for important VTE risk factors (for example, age, history of VTE, and recent pregnancy) and by including the maximally adjusted risk estimates in the present calculations; in addition, the findings were similar when poor-quality studies were excluded from the analysis. Statistical heterogeneity was present in most analyses.
Despite the presence of heterogeneity, the findings were generally robust in the subgroup and sensitivity analyses. Most of the exposure and outcome information came from large administrative databases. Although these databases offer greater assurance for capturing specific formulations and duration of use compared with self-report, prescription data may not accurately represent actual COC use at the time of the VTE event. 50, 51 In addition, the accuracy of administrative databases for the ascertainment of medical conditions such as VTE is variable; however, linking data from these databases to other sources (for example, physician report, evidence for anticoagulation treatment)
to verify information reduces the likelihood for misclassification.
In conclusion, the present meta-analysis indicated that COCs con- 
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